CO2020014399A2 - Composiciones farmacéuticas para el tratamiento de la deficiencia de esfingomielinasa ácida - Google Patents
Composiciones farmacéuticas para el tratamiento de la deficiencia de esfingomielinasa ácidaInfo
- Publication number
- CO2020014399A2 CO2020014399A2 CONC2020/0014399A CO2020014399A CO2020014399A2 CO 2020014399 A2 CO2020014399 A2 CO 2020014399A2 CO 2020014399 A CO2020014399 A CO 2020014399A CO 2020014399 A2 CO2020014399 A2 CO 2020014399A2
- Authority
- CO
- Colombia
- Prior art keywords
- acid sphingomyelinase
- treatment
- pharmaceutical compositions
- sphingomyelinase deficiency
- compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/04—Phosphoric diester hydrolases (3.1.4)
- C12Y301/04012—Sphingomyelin phosphodiesterase (3.1.4.12)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Biophysics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invención proporciona composiciones, tales como composiciones líquidas acuosas y composiciones liofilizadas, que comprenden una esfingomielinasa ácida humana recombinante. También se proporcionan métodos para usar las composiciones para el tratamiento de pacientes que tienen una deficiencia de esfingomielinasa ácida.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862676525P | 2018-05-25 | 2018-05-25 | |
PCT/US2019/033983 WO2019227029A1 (en) | 2018-05-25 | 2019-05-24 | Pharmaceutical compositions for treating acid sphingomyelinase deficiency |
Publications (1)
Publication Number | Publication Date |
---|---|
CO2020014399A2 true CO2020014399A2 (es) | 2020-12-10 |
Family
ID=66912954
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CONC2020/0014399A CO2020014399A2 (es) | 2018-05-25 | 2020-11-20 | Composiciones farmacéuticas para el tratamiento de la deficiencia de esfingomielinasa ácida |
Country Status (14)
Country | Link |
---|---|
US (1) | US20210145941A1 (es) |
EP (1) | EP3802805A1 (es) |
JP (1) | JP2024069459A (es) |
KR (1) | KR20210015903A (es) |
CN (1) | CN112424347A (es) |
AU (1) | AU2019275109A1 (es) |
BR (1) | BR112020023829A2 (es) |
CA (1) | CA3101688A1 (es) |
CO (1) | CO2020014399A2 (es) |
IL (1) | IL278964A (es) |
MX (1) | MX2020012700A (es) |
SG (1) | SG11202011488WA (es) |
UY (1) | UY38238A (es) |
WO (1) | WO2019227029A1 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW202403043A (zh) | 2022-03-18 | 2024-01-16 | 美商健臻公司 | 重組人類酸性鞘磷脂酶醫藥組合物及方法 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5773278A (en) | 1991-05-03 | 1998-06-30 | Mount Sinai Medical Center | Acid sphingomyelinase gene |
AR059089A1 (es) * | 2006-01-20 | 2008-03-12 | Genzyme Corp | Administracion intraventricular de una enzima para enfermedades de almacenamiento lisosomal |
EP1999270A4 (en) * | 2006-03-13 | 2010-04-28 | Perkinelmer Las Inc | SUBSTRATES AND INTERNAL STANDARDS FOR MASS SPECTROSCOPY DETECTION |
JP2012530721A (ja) * | 2009-06-18 | 2012-12-06 | ワイス・エルエルシー | 小モジュール免疫薬のための凍結乾燥製剤 |
RU2569744C2 (ru) | 2009-08-28 | 2015-11-27 | Маунт Синай Скул Оф Медсин | Ферментная заместительная терапия с увеличением дозы для лечения недостаточности кислой сфингомиелиназы |
RU2012154576A (ru) * | 2010-06-25 | 2014-07-27 | Шир Хьюман Дженетик Терапис, Инк. | Способы и композиции для доставки к цнс гепаран-n-сульфатазы |
FI126979B (en) * | 2016-02-29 | 2017-09-15 | Faron Pharmaceuticals Oy | Lyophilized pharmaceutical formulation and use thereof |
KR20200044064A (ko) * | 2017-08-24 | 2020-04-28 | 사노피 | 산성 스핑고미엘린분해효소 결핍증 환자에서의 비정상적 골병태의 치료 |
-
2019
- 2019-05-23 UY UY0001038238A patent/UY38238A/es not_active Application Discontinuation
- 2019-05-24 WO PCT/US2019/033983 patent/WO2019227029A1/en unknown
- 2019-05-24 AU AU2019275109A patent/AU2019275109A1/en active Pending
- 2019-05-24 SG SG11202011488WA patent/SG11202011488WA/en unknown
- 2019-05-24 MX MX2020012700A patent/MX2020012700A/es unknown
- 2019-05-24 EP EP19731419.8A patent/EP3802805A1/en active Pending
- 2019-05-24 CN CN201980048133.7A patent/CN112424347A/zh active Pending
- 2019-05-24 BR BR112020023829-5A patent/BR112020023829A2/pt unknown
- 2019-05-24 CA CA3101688A patent/CA3101688A1/en active Pending
- 2019-05-24 KR KR1020207037328A patent/KR20210015903A/ko active Search and Examination
-
2020
- 2020-11-20 CO CONC2020/0014399A patent/CO2020014399A2/es unknown
- 2020-11-25 IL IL278964A patent/IL278964A/en unknown
- 2020-11-25 US US17/104,593 patent/US20210145941A1/en active Pending
-
2024
- 2024-03-14 JP JP2024039768A patent/JP2024069459A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
CA3101688A1 (en) | 2019-11-28 |
AU2019275109A1 (en) | 2021-01-21 |
MX2020012700A (es) | 2021-04-28 |
BR112020023829A2 (pt) | 2021-05-11 |
WO2019227029A1 (en) | 2019-11-28 |
KR20210015903A (ko) | 2021-02-10 |
JP2024069459A (ja) | 2024-05-21 |
SG11202011488WA (en) | 2020-12-30 |
CN112424347A (zh) | 2021-02-26 |
JP2021525083A (ja) | 2021-09-24 |
UY38238A (es) | 2019-12-31 |
IL278964A (en) | 2021-01-31 |
EP3802805A1 (en) | 2021-04-14 |
US20210145941A1 (en) | 2021-05-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2019006291A2 (es) | Composiciones de aminoácidos y métodos de tratamiento de enfermedades hepáticas | |
CL2018001404A1 (es) | Inhibidores de bromodominio bivalentes y usos de los mismos. | |
EA201890725A1 (ru) | Агонисты фарнезоидного х-рецептора и их применение | |
BR112017011923A2 (pt) | bactéria modificada para tratar doenças associadas com hiperamonemia | |
WO2015117010A3 (en) | Bag3 as a target for therapy of heart failure | |
BR112017007975A2 (pt) | composições e métodos para o tratamento de disfunção das glândulas meibomianas | |
GT201400166A (es) | Miméticos de apelina sintéticos para el tratamiento de insuficiencia cardiaca | |
BR112016027773A2 (pt) | peptídeo célula-penetrante, polinucleotídeo, proteína recombinante célula penetrante de toxina botulínica, vetor de expressão recombinante, bactéria, composição farmacêutica, composição cosmética e método para produzir uma proteína recombinante célula-penetrante de toxina botulínica | |
BR112017009552A8 (pt) | Métodos para alvejar o controle transcricional em regiões de super-realçador | |
MX2019000588A (es) | Moduladores de la somatostatina y usos de los mismos. | |
BR112014009418A2 (pt) | macrociclos peptidomiméticos | |
CL2014000432A1 (es) | Compuestos derivados de clorofila o bacterioclorofila; composicion farmaceutica que los comprende; y metodo de tratamiento fotodinamico del adelgazamiento de la cornea o del estiramiento de la esclerotica. | |
CL2017002825A1 (es) | Formulaciones de tpp1 y métodos para tratar la enfermedad de cln2 | |
MX2022009155A (es) | Nuevos profarmacos polimericos de la hormona del crecimiento humana (hgh). | |
CL2019002368A1 (es) | Composiciones y métodos para el tratamiento de cáncer. | |
EA201992083A1 (ru) | Модуляторы соматостатина и их применения | |
ECSP12011962A (es) | Tratamientos para trastornos gastrointestinales | |
CO2021014008A2 (es) | Compuestos farmacéuticos para el tratamiento de trastornos mediados por complemento | |
BR112016015660A2 (pt) | formulação farmacêutica de neuregulina (nrg) e formulação farmacêutica liofilizada de neuregulina (nrg) | |
BR112018015367A2 (pt) | carreadores oromucosais de nanofibra para tratamento terapêutico | |
EA201792571A1 (ru) | Терапевтическое применение l-4-хлорокинуренина | |
EA201691567A1 (ru) | Способы лечения легких травм головного мозга | |
CO2020005485A2 (es) | Administración oral de análogos del péptido glp-1 | |
MX2017002948A (es) | Métodos de tratamiento para la sarcoidosis pulmonar. | |
UY37611A (es) | Formulaciones de evolocumab de alta concentración y baja viscosidad y métodos para elaborarlas |